a:5:{s:8:"template";s:5073:" {{ keyword }}
{{ text }}
";s:4:"text";s:5526:"About TERN-201 and Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibition. Inhibition of SSAO is believed to have therapeutic benefit for the treatment of NAFLD, NASH and other chronic fibrotic liver diseases by reducing oxidative stress and recruitment of white blood cells to the liver. SSAO, also known as VAP-1 (Vascular Adhesion Protein-1), is a dual-function amine oxidase which increases oxidative stress and promotes recruitment of white blood cells in the liver, which results in inflammation and hepatic fibrosis. About TERN-501 and Thyroid Hormone Receptor Beta (THR-β). Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation and fibrosis. Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. TERN-101: Farnesoid X Receptor (FXR) Agonism FXR is a nuclear receptor that is highly expressed in the liver and small intestine. Terns is an equal opportunity employer. TERN-201 is a potent SSAO inhibitor which provides an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver. In addition, the company is actively planning to initiate clinical studies for its thyroid hormone receptor-β agonist TERN-501 as monotherapy and in combination with its other pipeline assets for NASH, as well as advancing its small molecule GLP-1R agonist program. Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease including a pipeline of orally administered drug candidates for the treatment of non-alcoholic steatohepatitis (NASH). There is currently no approved medication for the treatment of NASH. Presenter: Martijn Fenaux About Terns Pharmaceuticals. TERN-501 is a highly potent and selective small molecule THR- β agonist. Steatosis is a key driver of NASH, a serious and progressive liver disease characterized by liver inflammation known as steatohepatitis. Certain MAOs could be associated with potential drug-drug interactions in the NASH patient population. Session: NAFLD: Experimental and Pathophysiology In a rat hypercholesterolemic model, a robust and dose-dependent reduction in total cholesterol of up to 71% (p < 0.0001 vs. vehicle) was observed. We and our partners will store and/or access information on your device through the use of cookies and similar technologies, to display personalised ads and content, for ad and content measurement, audience insights and product development. Terns is pursuing a novel therapeutic approach to selectively activate the β thyroid hormone receptor in the liver. TERN-201 is a potent and highly specific SSAO inhibitor with >7,000-fold in vitro selectivity for SSAO over off-target monoamine oxidases (MAO). ABOUT US OUR APPROACH There is currently no approved medication for the treatment of NASH. The abstracts were published in the October supplement of Hepatology, the peer-reviewed journal of AASLD. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Thyroid hormone receptor beta (THR-β) is a nuclear hormone receptor that is highly expressed in the liver and plays a central role in lipid metabolism, regulation of blood cholesterol and triglyceride levels, and prevention of steatosis caused by excess fat buildup in the liver. TERN-201 has demonstrated potential in a preclinical setting as an SSAO inhibitor which provides an additional treatment mechanism for NASH. Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver … Both programs also demonstrated strong preclinical data. TERNS 1065 East Hillsdale Blvd., Suite 100 Foster City, CA 94404 info@ternspharma.com Fax: +1 650-275-4395. Our Vision. Mark Vignola Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease including a pipeline of orally administered drug candidates for the treatment of non-alcoholic steatohepatitis (NASH). Terns announced in July 2020 positive Phase 1 clinical data for its highly-selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement. - Clinical trial of SSAO Inhibitor TERN-201 in NASH patients planned for early 2021 -. Presenter: Christopher Jones, Poster Title: Multiple ascending doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, fully suppresses plasma SSAO activity in a Phase 1 study ABOUT US OUR APPROACH PIPELINE We look forward to continuing our momentum into next year, when we anticipate having results from several clinical studies within our NASH development programs, including the Phase 2a LIFT study of TERN-101 in NASH patients, the TERN-501 first-in-human Phase 1 monotherapy results, and a Phase 1 study of TERN-101 co-administered with TERN-501.”, Poster Title: Combination of TERN-101, a farnesoid X receptor agonist, and TERN-501, a selective agonist of thyroid hormone receptor beta, reduces activation of inflammatory and fibrotic gene pathways in a mouse model of non-alcoholic steatohepatitis ";s:7:"keyword";s:26:"terns pharmaceuticals nash";s:5:"links";s:1033:"Edna Metabarcoding, Nc Restaurant Inspection Grades, Carle Clinic Bloomington, Il, Daft Login, Curtin University Building 418, Hisham Name Meaning, Williamson Medical Center Billing, Boston Scientific Stock Performance, Daft Login, ";s:7:"expired";i:-1;}